NEW YORK, July 19, 2026 – Shares of Pfizer (NYSE:PFE) advanced 3.6% last week, outperforming the broader market as the pharmaceutical giant's dividend appeal drew income-seeking investors. The stock closed at $25.05 on Friday, July 17, beating the S&P 500 by 5.2 percentage points during a period when the index slipped 1.6%.
The rally occurred despite unchanged consensus estimates from analysts. Projected earnings for 2026 now stand at $2.94 per share, a decrease of two cents from three months ago. This slight downward revision highlights that the recent price movement is driven more by income considerations than by expectations of earnings growth.
Pfizer's annualized dividend of $1.72 per share yields 6.9% at the current price, a figure that stands out in a low-yield environment. The company's price-to-estimate ratio ended the week at 8.5, suggesting the stock remains attractively valued relative to earnings projections. Average daily trading volume rose to 44.7 million shares, 9.7% above the 65-day average, indicating heightened investor interest.
The broader pharmaceutical sector also saw gains. Bristol Myers Squibb (NYSE:BMY) led the group with a 5.5% weekly rise to $60.74. Merck & Co. (NYSE:MRK) added 3.2% to close at $127.50, and AbbVie (NYSE:ABBV) climbed 2.6% to $254.49. In contrast, Eli Lilly (NYSE:LLY) fell 0.8% to $1,179.11. The defensive nature of these stocks likely contributed to their relative strength as the overall market declined.
On the corporate front, Pfizer faces a minor supply issue in India. The company has suspended sales of its Premarin vaginal cream in the Indian market, citing supply challenges. The product generated only $2.76 million in revenue in India over the year ending in June, representing approximately 0.005% of Pfizer's annual revenue based on the midpoint of its guidance. While the disruption affects patients, its financial impact on the company is negligible.
A more significant development came on July 10, when the U.S. Food and Drug Administration expanded the approved use of Padcev in combination with Merck's Keytruda for treating muscle-invasive bladder cancer. The therapy, developed with Astellas Pharma (TYO:4503), showed a 47% reduction in the rate of recurrence, progression, or death, and a 35% lower risk of mortality compared to standard treatment. Aamir Malik, Pfizer's chief of U.S. commercial operations, called the approval a "historic turning point." However, unchanged second-quarter forecasts suggest the immediate earnings impact remains limited.
Pfizer shares will trade ex-dividend on Friday, July 24, with a payout of $0.43 per share. The company is not scheduled to release an earnings report this week; second-quarter results are expected on August 4.
Looking ahead, risks include a projected $1.5 billion decline in COVID-19-related revenue and a $1.5 billion exclusivity loss in 2026. The dividend yield could face pressure if clinical trials disappoint or if adoption of oncology treatments lags expectations.
